肠外铁剂过量:一项范围综述
该范围综述纳入1995至2025年发表的17篇报告共49例患者,大多数为单病例报告(82.4%)且近半为会议摘要(47.1%)。暴露分为急性单次过量(41.4%)和亚急性累积过量(58.6%),后者以氢氧化铁聚麦芽糖复合物为主(76.5%)。血清铁浓度与临床严重度不一致:825至>2000 µg/dL可无症状,而约112 µg/dL却出现休克、DIC和多器官衰竭;肝毒性主要见于亚急性累积病例(82.4%),急性病例未见。螯合治疗实践差异大,48/49例存活。结论提示口服铁阈值可能不适用,管理应依据临床轨迹。
要点
- 肠外铁剂过量是异质性综合征,包括无症状高铁血症、类输液反应和亚急性肝铁负载综合征,与经典口服铁中毒不同。
- 血清铁浓度不能可靠反映毒性:825至>2000 µg/dL可无症状,而约112 µg/dL却发生休克、DIC和多器官衰竭。
- 亚急性累积过量以氢氧化铁聚麦芽糖复合物为主(76.5%),肝毒性主要见于此类病例(82.4%),急性单次过量病例未见肝毒性。
- 螯合治疗实践差异大:4例急性过量患者在血清铁1301-1830 µg/dL未螯合而康复,另有无症状患者接受延长螯合。
- 现有证据以低量病例数据为主(17篇报告49例,82.4%为单病例报告,47.1%为会议摘要),结论仅为假设生成性。
适用人群与场景
- 纳入:描述人类肠外铁剂过量或超治疗性重复给药且提供足够原始临床细节的报告。
- 排除:原文未提及。
- 场景:原文未明确限定急诊、ICU或院前场景。
诊断标准与关键阈值
- 原文未提及明确的诊断标准或关键阈值;文中指出广泛引用的血清铁浓度阈值500 µg/dL主要源自口服铁中毒,可能不直接适用于肠外暴露。
处置流程与药物剂量
- 原文未提及具体的处置流程或药物剂量;文中指出螯合决策可能应更多依据临床轨迹和暴露表型而非仅血清铁浓度。
- 螯合实践差异大:4例急性过量患者在血清铁1301-1830 µg/dL未螯合而康复,另有无症状患者接受延长螯合。
红旗征与不能漏的情况
- 原文提及一例血清铁约112 µg/dL却出现休克、弥散性血管内凝血和多器官衰竭,提示低血清铁浓度也不能排除严重中毒。
- 亚急性累积病例中肝毒性报告占82.4%,需警惕肝损伤。
研究设计与关键结果
- 研究类型:范围综述,遵循Arksey和O'Malley框架及PRISMA-ScR报告规范。
- 样本量与中心数:17篇报告共49例患者,发表于1995至2025年;14/17(82.4%)为单病例报告,8/17(47.1%)为会议摘要。
- 人群:人类肠外铁剂过量或超治疗性重复给药报告。
- 暴露模式:急性单次过量12/29可分类病例(41.4%),亚急性累积过量17/29(58.6%);急性报告以蔗糖铁和右旋糖酐铁为主,亚急性以氢氧化铁聚麦芽糖复合物为主(76.5%)。
- 关键结果:血清铁浓度与临床严重度不一致(825至>2000 µg/dL可无症状,约112 µg/dL出现休克、DIC和多器官衰竭);肝毒性主要见于亚急性累积病例(82.4%),急性病例未见;48/49例存活。
- 螯合实践:4例急性过量患者血清铁1301-1830 µg/dL未螯合而康复,另有无症状患者接受延长螯合。
证据类型、等级与局限
- 证据类型:范围综述,纳入文献以单病例报告(82.4%)和会议摘要(47.1%)为主,证据量和异质性有限。
- 证据等级或推荐强度:原文未提及正式分级;作者指出观察结果应视为假设生成性。
- 局限:证据数量有限、质量异质,以低量病例数据为主;作者呼吁标准化报告和多中心药物警戒合作。
对床旁实践的改变
- 肠外铁剂过量不能直接套用口服铁中毒的血清铁阈值(如500 µg/dL)进行风险分层。
- 螯合决策应更多依据临床轨迹和暴露表型(急性单次 vs 亚急性累积),而非仅依赖血清铁浓度。
- 对亚急性累积过量患者应警惕肝毒性;对急性过量患者即使血清铁浓度高,也可能无需螯合即可康复。
- 适用与不适用人群:原文未明确排除人群;结论基于49例病例报告,不能外推为通用推荐。
指南或共识出处
- 原文未提及具体的指南或共识名称;引用文献为范围综述自身纳入的17篇报告。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Parenteral iron formulations are increasingly used worldwide for the treatment of iron deficiency anemia, yet clinical guidance for managing parenteral iron overdose is limited. Existing risk assessment and management frameworks, including the widely cited serum iron concentration threshold of 500 µg/dL, are derived primarily from oral iron poisoning and may not be directly applicable to parenteral exposures. This scoping review aims to map the existing literature on parenteral iron overdose, summarize exposure patterns, clinical presentations, laboratory findings, therapeutic interventions, and outcomes, and identify knowledge gaps to inform future clinical practice and research.
METHODS: A scoping review was conducted following the Arksey and O'Malley framework and reported in accordance with the PRISMA extension for scoping reviews. Embase, Ovid MEDLINE, and Cochrane CENTRAL were searched through 31 December 2025, supplemented by Google Scholar and citation searching. Eligible studies described human reports of parenteral iron overdose or supratherapeutic repeated administration with sufficient original clinical detail. Two reviewers independently screened studies and extracted data, with disagreements resolved by a third reviewer. Findings were synthesized descriptively, and recurring patterns were identified through thematic analysis.
RESULTS: Seventeen reports comprising 49 patients, published between 1995 and 2025, met the inclusion criteria. Most reports were single-patient case reports (14/17, 82.4%), and nearly half were conference abstracts (8/17, 47.1%), reflecting an evidence base composed predominantly of low-volume, case-level data. Exposures clustered into acute single-dose overdose (12/29 classifiable cases, 41.4%) and subacute cumulative overexposure (17/29, 58.6%). Iron sucrose and iron dextran predominated among acute reports, whereas ferric hydroxide polymaltose complex predominated among subacute cases (76.5%). Serum iron concentration did not consistently correspond to clinical severity: several cases with concentrations between 825 and greater than 2,000 µg/dL remained asymptomatic, whereas one case with a concentration of approximately 112 µg/dL developed shock, disseminated intravascular coagulation, and multiorgan failure. Liver toxicity was reported mainly in subacute cumulative cases (82.4%) but in none of the acute cases. Chelation practice varied widely: four acute overdose patients recovered without chelation despite serum iron concentrations of 1,301-1,830 µg/dL, whereas asymptomatic patients in other reports received prolonged chelation. Overall, 48 of the 49 included patients survived.
DISCUSSION: The findings converge on three recurring themes. Parenteral iron overdose appears to represent a heterogeneous clinical syndrome distinct from classic oral iron poisoning, with phenotypes ranging from asymptomatic hyperferremia to infusion reaction-like presentations and subacute hepatic iron-loading syndromes. Conventional laboratory markers, particularly serum iron concentration, may not reliably reflect toxicologically active iron after parenteral exposure, likely reflecting biphasic kinetics, formulation-dependent iron release, and analytical interference from carbohydrate-bound iron. Chelation decisions may be better informed by clinical trajectory and exposure phenotype than by serum iron concentration alone.
CONCLUSION: Parenteral iron overdose appears to differ from oral iron poisoning in pathophysiology, laboratory behavior, and management considerations. Oral iron thresholds may not be directly applicable, and management may be better guided by clinical trajectory than by laboratory values alone. Given the limited quantity and heterogeneous quality of existing evidence, these observations should be interpreted as hypothesis-generating. Standardized reporting of parenteral iron overdose and multicenter pharmacovigilance collaborations are needed to clarify the true incidence and severity spectrum of this underrecognized medication safety issue.
参考来源
- Chen HH, Wu SH, Mu HW, et al. Parenteral iron overdose: a scoping review. Clin Toxicol (Phila). 2026. PMID: 42708798. doi:10.1080/15563650.2026.2727916
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。